201 related articles for article (PubMed ID: 23593363)
1. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.
Riganti C; Castella B; Kopecka J; Campia I; Coscia M; Pescarmona G; Bosia A; Ghigo D; Massaia M
PLoS One; 2013; 8(4):e60975. PubMed ID: 23593363
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.
Salaroglio IC; Campia I; Kopecka J; Gazzano E; Orecchia S; Ghigo D; Riganti C
Oncotarget; 2015 Jan; 6(2):1128-42. PubMed ID: 25544757
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Pinzòn-Daza ML; Giordano A; Desiderio V; Ghigo D; De Rosa G; Caraglia M; Riganti C
Oncotarget; 2016 Apr; 7(15):20753-72. PubMed ID: 26980746
[TBL] [Abstract][Full Text] [Related]
4. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Giordano A; Desiderio V; Ghigo D; Caraglia M; De Rosa G; Riganti C
Oncotarget; 2015 Oct; 6(31):31461-78. PubMed ID: 26372812
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
Rigoni M; Riganti C; Vitale C; Griggio V; Campia I; Robino M; Foglietta M; Castella B; Sciancalepore P; Buondonno I; Drandi D; Ladetto M; Boccadoro M; Massaia M; Coscia M
Oncotarget; 2015 Oct; 6(30):29833-46. PubMed ID: 26284584
[TBL] [Abstract][Full Text] [Related]
6. Ailanthone reverses multidrug resistance by inhibiting the P-glycoprotein-mediated efflux in resistant K562/A02 cells.
Han F; Liu G; Sun C; Wei J
Cell Mol Biol (Noisy-le-grand); 2018 Dec; 64(15):55-61. PubMed ID: 30672437
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
8. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.
De Boo S; Kopecka J; Brusa D; Gazzano E; Matera L; Ghigo D; Bosia A; Riganti C
Mol Cancer; 2009 Nov; 8():108. PubMed ID: 19925669
[TBL] [Abstract][Full Text] [Related]
9. Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Singh NS; Bernier M; Wainer IW
Pharmacol Res; 2016 Sep; 111():757-766. PubMed ID: 27423937
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
11. A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
Liu RM; Xu P; Chen Q; Feng SL; Xie Y
Phytomedicine; 2020 Dec; 79():153342. PubMed ID: 32992085
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
14. Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells.
Zhang H; Sun L; Xiao X; Xie R; Liu C; Wang Y; Wei Y; Zhang H; Liu L
Cancer Sci; 2014 Sep; 105(9):1109-15. PubMed ID: 25040744
[TBL] [Abstract][Full Text] [Related]
15. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil.
Pesić M; Podolski A; Rakić L; Ruzdijić S
Invest New Drugs; 2010 Aug; 28(4):482-92. PubMed ID: 19533022
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
[TBL] [Abstract][Full Text] [Related]
17. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
18. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.
Ye S; Zhang J; Shen J; Gao Y; Li Y; Choy E; Cote G; Harmon D; Mankin H; Gray NS; Hornicek FJ; Duan Z
Br J Pharmacol; 2016 Feb; 173(3):613-26. PubMed ID: 26603906
[TBL] [Abstract][Full Text] [Related]
19. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
20. Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells.
Chang YT; Wang CCN; Wang JY; Lee TE; Cheng YY; Morris-Natschke SL; Lee KH; Hung CC
Phytomedicine; 2019 Feb; 53():252-262. PubMed ID: 30668405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
